Search research articles
Contact Us
Filters
Showing results (1-10 of 206) with videos related to
Page
of 21
Sort By:
Pharmaceutisch Weekblad. Scientific Edition
|
June 19, 1992
Metabolism of valproate to hepatotoxic intermediates
T A Baillie
Drug Metabolism Reviews
|
November 21, 2014
The contributions of Sidney D. Nelson to drug metabolism research
Thomas A Baillie
Expert Opinion on Drug Discovery
|
October 2, 2020
Approaches to mitigate the risk of serious adverse reactions in covalent drug design
Thomas A Baillie
Chemical Research in Toxicology
|
July 18, 2006
Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology
Thomas A Baillie
Angewandte Chemie (International Ed. in English)
|
August 20, 2016
Targeted Covalent Inhibitors for Drug Design
Thomas A Baillie
Chemical Research in Toxicology
|
February 17, 2009
Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials
Thomas A Baillie
Chemical Research in Toxicology
|
December 7, 2007
Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism
Thomas A Baillie
Accounts of Chemical Research
|
September 20, 2013
Distinctive activation and functionalization of hydrocarbon C-H bonds initiated by Cp*W(NO)(η(3)-allyl)(CH2CMe3) complexes
Rhett A Baillie, Peter Legzdins
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
March 1, 1993
Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations
K Kassahun, T A Baillie
Science (New York, N.Y.)
|
March 20, 2004
Organic chemistry in drug discovery
Malcolm MacCoss, Thomas A Baillie
Page
of 21
Search research articles
Search
Showing results (1-10 of 206) with videos related to
Sort By:
Page
of 21
Pharmaceutisch Weekblad. Scientific Edition
|
June 19, 1992
Metabolism of valproate to hepatotoxic intermediates
T A Baillie
Drug Metabolism Reviews
|
November 21, 2014
The contributions of Sidney D. Nelson to drug metabolism research
Thomas A Baillie
Expert Opinion on Drug Discovery
|
October 2, 2020
Approaches to mitigate the risk of serious adverse reactions in covalent drug design
Thomas A Baillie
Chemical Research in Toxicology
|
July 18, 2006
Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology
Thomas A Baillie
Angewandte Chemie (International Ed. in English)
|
August 20, 2016
Targeted Covalent Inhibitors for Drug Design
Thomas A Baillie
Chemical Research in Toxicology
|
February 17, 2009
Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials
Thomas A Baillie
Chemical Research in Toxicology
|
December 7, 2007
Metabolism and toxicity of drugs. Two decades of progress in industrial drug metabolism
Thomas A Baillie
Accounts of Chemical Research
|
September 20, 2013
Distinctive activation and functionalization of hydrocarbon C-H bonds initiated by Cp*W(NO)(η(3)-allyl)(CH2CMe3) complexes
Rhett A Baillie, Peter Legzdins
Drug Metabolism and Disposition: the Biological Fate of Chemicals
|
March 1, 1993
Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations
K Kassahun, T A Baillie
Science (New York, N.Y.)
|
March 20, 2004
Organic chemistry in drug discovery
Malcolm MacCoss, Thomas A Baillie
Page
of 21